BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Biotech Bay

  Exelixis To Release Third Quarter 2017 Financial Results On Wednesday, November 1, 2017

  Exelixis announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017.

  October 18, 2017

   · 

  2 min read
• Drug Development

  BioLineRx Announces Initiation of Phase Ib/2 Trial for BL-80040 in Gastric Cancer Under Immunotherapy Collaboration

  BioLineRx announced today that Genentech has commenced a Phase 1b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy agent.

  October 18, 2017

   · 

  6 min read
• Biotech Bay

  Episona Enters Consumer Market with Epigenetics Test for Male Infertility

  Episona announced today that it is entering the consumer market with the first at-home, epigenetics-based test for evaluating male infertility.

  October 18, 2017

   · 

  4 min read
• 

  FDA

  FDA Green Lights OptiScan’s Glucose Monitoring System for the ICU

  The OptiScanner 5000 is the first-of-its-kind automated bedside glucose monitoring system that provides physicians information to manage patient glucose levels in the ICU.

  October 18, 2017

   · 

  4 min read
• Medicenna Announces Trading on the OTCQX Best Market in the United States

  Medicenna is pleased to announce that the Company has received approval to commence trading on the OTCQX Best Market, under the symbol, “MDNAF”.

  October 18, 2017

   · 

  4 min read
• Pharm Country

  Novartis Drug Promacta Shows Long-Term Disease Control For Chronic/Persistent Immune Thrombocytopenia

  Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with chronic/persistent immune (idiopathic) thrombocytopenia (ITP).

  October 18, 2017

   · 

  15 min read
• Deals

  Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

  Optinose announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $16.00 per share.

  October 18, 2017

   · 

  3 min read
• Biotech Beach

  Prometheus Laboratories Release: New Test Monitors Therapeutic Ustekinumab Levels In IBD Patients

  Prometheus Laboratories Inc. announces a new therapeutic drug monitoring test for use in adult inflammatory bowel disease (IBD) patients treated with Stelara (ustekinumab).

  October 18, 2017

   · 

  2 min read
• Policy

  Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT Patent Litigation

  Under the agreement, Neos has granted Actavis the right to manufacture and market its generic version of Adzenys XR-ODT under the Actavis ANDA beginning on September 1, 2025, or earlier under certain circumstances.

  October 18, 2017

   · 

  3 min read
• Business

  Pharmazz has Received Exclusive License to U.S. Patent for Treatment of Opioid Tolerance And Pain Management

  Pharmazz has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management. Inadequate pain control is a major public health concern in the USA.

  October 18, 2017

   · 

  2 min read